INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Other Events

Item 8.01.Other Events.

On May5, 2017, GlaxoSmithKline plc and Innoviva,Inc. (Innoviva)
distributed a press release announcing positive results from the
Salford Lung Study (SLS) of RELVAR ELLIPTA 100/25mcg or 200/25mcg
(fluticasone furoate FF/vilanterol VI or FF/VI) in asthma. SLS is
a Phase IIIb multi-center, open label randomized controlled
trial. The objective of SLS was to compare the effectiveness and
safety profile of initiating treatment with FF/VI with usual
asthma maintenance therapy over a 52 week period.

FF/VI has been developed under the 2002 Long-Acting Beta2 Agonist
(LABA) collaboration between Glaxo Group Limited and Innoviva.
FF/VI 100/25mcg, under the brand name RELVAR ELLIPTA, is
indicated in Europe in the regular treatment of patients aged 12
and over with asthma, where use of a combination product is
appropriate. In the United States, FF/VI 100/25mcg, under the
brand name BREO ELLIPTA, is indicated as a once-daily treatment
of asthma in patients aged 18 years and older and is not
indicated for the relief of acute bronchospasm.

The press release is filed as Exhibit99.1 to this report and is
incorporated herein by reference.

Item9.01. Financial Statements and Exhibits.

(d)Exhibits

About INNOVIVA, INC. (NASDAQ:INVA)

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

INNOVIVA, INC. (NASDAQ:INVA) Recent Trading Information

INNOVIVA, INC. (NASDAQ:INVA) closed its last trading session up +0.04 at 11.51 with 837,558 shares trading hands.